John M. McLaughlin

Pfizer, Inc.

235 East 42 Street

New York, NY 10017

United States

SCHOLARLY PAPERS

11

DOWNLOADS
Rank 7,610

SSRN RANKINGS

Top 7,610

in Total Papers Downloads

11,131

SSRN CITATIONS
Rank 28,410

SSRN RANKINGS

Top 28,410

in Total Papers Citations

41

CROSSREF CITATIONS

0

Scholarly Papers (11)

1.

Six-Month Effectiveness of BNT162B2 mRNA COVID-19 Vaccine in a Large US Integrated Health System: A Retrospective Cohort Study

Number of pages: 40 Posted: 23 Aug 2021
Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente - Southern California Kaiser Permanente Medical Group, Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California, Kaiser Permanente - Southern California Kaiser Permanente Medical Group, Kaiser Permanente - Kaiser Permanente Center for Integrated Health Care Research, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs and Pfizer, Inc.
Downloads 5,580 (2,875)

Abstract:

Loading...

2.

BNT162b2 (Pfizer–Biontech) mRNA COVID-19 Vaccine Against Omicron-Related Hospital and Emergency Department Admission in a Large US Health System: A Test-Negative Design

Number of pages: 25 Posted: 18 Jan 2022
Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs and Pfizer, Inc.
Downloads 2,110 (14,262)

Abstract:

Loading...

omicron, effectiveness, waning, booster, third dose, BNT162b2, SARS-CoV-2, COVID-19, United States, test-negative, kaiser

3.

Nationwide Vaccination Campaign with BNT162b2 in Israel Demonstrates High Vaccine Effectiveness and Marked Declines in Incidence of SARS-CoV-2 Infections and COVID-19 Cases, Hospitalizations, and Deaths

Number of pages: 24 Posted: 24 Mar 2021
Ministry of Health (Israel) - Public Health Services, Pfizer, Inc., Pfizer, Inc., Ministry of Health (Israel) - Public Health Services, Ministry of Health (Israel) - Public Health Services, Pfizer, Inc., Ministry of Health (Israel) - Information Technology Department, Ministry of Health (Israel) - Information Technology Department, Pfizer Pharmaceuticals Israel Ltd, Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Harvard University - Center for Communicable Disease Dynamics, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Ministry of Health (Israel) and Ministry of Health (Israel) - Department of Maternal and Child Health
Downloads 1,663 (20,682)
Citation 1

Abstract:

Loading...

COVID-19, SARS-CoV-2, vaccine effectiveness, prevention, mRNA vaccines, pandemic, observational study, epidemiology

4.

Infections, Hospitalizations, and Deaths Averted Via Direct Effects of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Vaccination Campaign, Israel

Number of pages: 25 Posted: 13 May 2021
Ministry of Health (Israel) - Public Health Services, Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Yale UniversityMinistry of Health (Israel) - Public Health Services, Harvard T.H. Chan School of Public Health - Center for Communicable Disease Dynamics, Ministry of Health (Israel) - Public Health Services, Pfizer Pharmaceuticals Israel Ltd, Ministry of Health (Israel) - Information Technology Department, Ministry of Health (Israel) - Information Technology Department, Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Harvard University - Center for Communicable Disease Dynamics, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Ministry of Health (Israel) and Ministry of Health (Israel) - Department of Maternal and Child Health
Downloads 467 (116,645)
Citation 1

Abstract:

Loading...

COVID-19, SARS-CoV-2, cases averted, impact, hospitalizations, deaths, Israel, model, public health, pandemic

5.

BNT162b2 Effectiveness and Durability Against BA.1 and BA.2 Hospital and Emergency Department Admissions in a Large US Health System: A Test-Negative Design

Number of pages: 25 Posted: 30 Jun 2022
Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs and Pfizer, Inc.
Downloads 386 (145,419)
Citation 1

Abstract:

Loading...

BA.2, BA.1, omicron, effectiveness, BNT162b2, SARS-CoV-2, COVID-19, United States, test-negative, Kaiser Permanente, real-world

6.

Effectiveness of a Third Dose of BNT162b2 mRNA COVID-19 Vaccine in a Large US Health System: A Retrospective Cohort Study

Number of pages: 35 Posted: 21 Dec 2021
Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente - Kaiser Permanente Center for Integrated Health Care Research, Kaiser Permanente Southern California, Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs and Pfizer, Inc.
Downloads 381 (147,488)
Citation 5

Abstract:

Loading...

effectiveness, waning, booster, third dose, BNT162b2, SARS-CoV-2, COVID-19, United States, cohort, delta

7.

Effectiveness of BNT162b2 mRNA COVID-19 Vaccine Against SARS-CoV-2 Variant Beta (B.1.351) Among Persons Identified Through Contact Tracing in Israel

Number of pages: 29 Posted: 13 Aug 2021
Ministry of Health (Israel) - Public Health Services, Pfizer, Inc., Harvard University - Center for Communicable Disease Dynamics, Pfizer, Inc., Ministry of Health (Israel), Israel Ministry of Health, Yale UniversityMinistry of Health (Israel) - Public Health Services, Sheba Medical Center - Central Virology Laboratory, Sheba Medical Center - Central Virology Laboratory, Sheba Medical Center - Central Virology Laboratory, Chaim Sheba Medical Center - Central Virology Laboratory, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Pfizer, Inc., Pfizer Pharmaceuticals Israel Ltd, Harvard T.H. Chan School of Public Health - Center for Communicable Disease Dynamics, Ministry of Health (Israel) - Public Health Services, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Ministry of Health (Israel) and Ministry of Health (Israel) - Department of Maternal and Child Health
Downloads 188 (299,496)
Citation 1

Abstract:

Loading...

8.

Effectiveness of the BNT162b2 XBB.1.5-Adapted Vaccine Against COVID-19 Hospitalization Related to the JN.1 Variant in Europe: A Test-Negative Case-Control Study Using the id.Drive Platform

Number of pages: 37 Posted: 11 Jun 2024
Pfizer, Inc., P95 Pharmacovigilance and Epidemiology Services, Pfizer, Inc., P95 Pharmacovigilance and Epidemiology Services, P95 Pharmacovigilance and Epidemiology Services, Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Autonomous University of Barcelona - Hospital Universitari Vall d'Hebron, University Hospital Ulm, P95 Pharmacovigilance and Epidemiology Services, P95 Pharmacovigilance and Epidemiology Services, University Hospital Ulm, University of Genova - Department of Health Sciences, Ziekenhuis Netwerk Antwerpen (ZNA), Centre Hospitalier Universitaire St-Pierre, FISABIO-Public Health, Universitat Autònoma de Barcelona (UAB), Instituto de Salud Carlos III, Goethe University Frankfurt, Freiburg University, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Pfizer, Inc. and P95 Pharmacovigilance and Epidemiology Services
Downloads 133 (411,986)

Abstract:

Loading...

COVID-19, SARS-CoV-2, COVID-19 vaccination, vaccine effectiveness, BNT162b2, XBB adapted vaccine, JN.1

9.

Incidence of Community Acquired Lower Respiratory Tract Disease in Bristol, UK During the COVID-19 Pandemic

Number of pages: 31 Posted: 19 Apr 2022
University of Bristol - Population Health Sciences, University of Bristol - Department of Mathematics, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, University Hospitals Bristol NHS Foundation Trust - Clinical Research and Imaging Centre, University of Bristol - Academic Respiratory Unit, University of Bristol - Department of Population Health Sciences, University of Bristol - Population Health Sciences, University of Bristol - Department of Population Health Sciences, Pfizer, Inc., Pfizer, Inc., University of Bristol - Bristol Vaccine Centre, Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., University of Bristol - Department of Population Health Sciences, University of Bristol - Academic Respiratory Unit, Pfizer Inc. - Medical and Scientific Affairs, University of Bristol - Engineering Mathematics and University of Bristol - Bristol Vaccine Centre
Downloads 109 (464,560)
Citation 4

Abstract:

Loading...

pneumonia, lower respiratory tract infection, cardiac failure, COVID-19, SARS-CoV-2

10.

County-Level Vaccination Coverage and Rates of COVID-19 Cases and Deaths in the United States

Number of pages: 30 Posted: 20 Aug 2021
Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Harvard University - Center for Communicable Disease Dynamics and Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs
Downloads 73 (597,728)
Citation 3

Abstract:

Loading...

11.

Risk Factors for Long Covid in a United States Prospective Longitudinal Community-Based Cohort

Number of pages: 51 Posted: 24 Apr 2024
City University of New York (CUNY) - Institute for Implementation Science in Population Health, City University of New York, City University of New York, City University of New York (CUNY) - Institute for Implementation Science in Population Health, City University of New York, affiliation not provided to SSRN, Pfizer, Inc., Pfizer, Inc., City University of New York, City University of New York, Pfizer, Inc. and City University of New York (CUNY) - Institute for Implementation Science in Population Health
Downloads 41 (788,246)

Abstract:

Loading...

Long COVID, COVID-19 vaccine, Quality of Life, Poor Physical Health Days, Risk Factors, Post COVID-19 Conditions, Post acute sequalae of COVID-19